RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.3389%2Ffcvm.2022.96192035
https://w3id.org/ripe/ripe-kg/work/10.3389%2Ffcvm.2022.96192035
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1136%2Fbmj-2024-083382Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8) |
http://purl.org/spar/cito/cites |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
ripekg:work/10.1136%2Fbmj-2024-083382e083382 | the bmj Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies |
http://purl.org/spar/cito/cites |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
prism:doi |
10.3389/fcvm.2022.96192035 |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
dcterms:title |
Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
rdf:type |
node1 |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
rdf:type |
rdfs:Resource |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
rdf:type |
owl:Thing |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
rdf:type |
prov:Entity |
ripekg:work/10.3389%2Ffcvm.2022.96192035Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging |
rdf:type |
ripe:WorkWork |